EU/3/16/1726 - orphan designation for treatment of glycogen storage disease type II (Pompe's disease)

recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues

Overview

On 29 August 2016, orphan designation (EU/3/16/1726) was granted by the European Commission to NanoMedSyn, France, for recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues for the treatment of glycogen storage disease type II (Pompe's disease).

What is glycogen storage disease type II (Pompe's disease)?

Glycogen storage disease type II, also known as Pompe's disease, is an inherited disorder caused by the lack of an enzyme called acid alpha glucosidase (GAA). This enzyme is contained in lysosomes (part of the body's cells that break down nutrients and other materials). GAA breaks down glycogen (a complex sugar stored in the body) into glucose (a simpler sugar). When this enzyme is lacking, large amounts of glycogen build up in the muscles, including the heart and diaphragm (the main breathing muscle under the lungs). The progressive build-up of glycogen causes a wide range of signs and symptoms, including heart problems, breathing difficulties and muscle weakness.

Glycogen storage disease type II is a long-term debilitating and life-threatening disease because it causes breathing and heart problems and is associated with premature death.

What is the estimated number of patients affected by the condition?

At the time of designation, glycogen storage disease type II affected approximately 0.3 in 10,000 people in the European Union (EU). This was equivalent to a total of around 15,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 513,700,000 (Eurostat 2016).

What treatments are available?

At the time of designation, Myozyme (alglucosidase alfa) was authorised for the treatment of glycogen storage disease type II in the EU. Myozyme is an 'enzyme replacement therapy' that works by replacing the missing GAA enzyme.

The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with glycogen storage disease type II. This is because early studies in the laboratory suggest that it can improve muscle function and regeneration better than existing therapies. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

The medicine is a version of the GAA enzyme. It has been modified by the addition of a compound to improve the uptake of GAA by muscle cells and to increase entry into the lysosomes, where it replaces the missing enzyme.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, no clinical trials with the medicine in patients with glycogen storage disease type II had been started.

At the time of submission, the medicine was not authorised anywhere in the EU for glycogen storage disease type II or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 13 July 2016 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/16/1726 : Public summary of opinion on orphan designation: Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues for the treatment of glycogen storage disease type II (Pompe’s diseas...

Adopted

Key facts

• Active substance:
  recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues
• Intended use:
  Treatment of glycogen storage disease type II (Pompe's disease)
• Orphan designation status:
  Positive
• EU designation number:
  EU/3/16/1726
• Date of designation:
  29/08/2016
• Sponsor:

  NanoMedSyn; 15 Avenue Charles Flahault; Faculté de Pharmacie; Bât E 2ème étage; 34093 Montpellier cedex 5; France; Tel. [phone]; E-mail: [e-mail]

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.